CG Oncology, Net Worth
CG Oncology, Net Worth Breakdown | CGON |
CG Oncology, Net Worth Analysis
CG Oncology,'s net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including CG Oncology,'s financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of CG Oncology,'s overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform CG Oncology,'s net worth analysis. One common approach is to calculate CG Oncology,'s market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares CG Oncology,'s stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing CG Oncology,'s net worth. This approach calculates the present value of CG Oncology,'s future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of CG Oncology,'s cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate CG Oncology,'s net worth. This involves comparing CG Oncology,'s financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into CG Oncology,'s net worth relative to its peers.
Enterprise Value |
|
To determine if CG Oncology, is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding CG Oncology,'s net worth research are outlined below:
| CG Oncology, Common has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 204 K. Net Loss for the year was (48.61 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| CG Oncology, generates negative cash flow from operations | |
| Over 92.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from investing.com: CG Oncologys SWOT analysis bladder cancer stock poised for pivotal results |
Follow CG Oncology,'s market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.35 B.Market Cap |
|
Project CG Oncology,'s profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.24) | (0.26) | |
| Return On Capital Employed | (0.30) | (0.31) | |
| Return On Assets | (0.24) | (0.26) | |
| Return On Equity | (0.26) | (0.28) |
When accessing CG Oncology,'s net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures CG Oncology,'s profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of CG Oncology,'s profitability and make more informed investment decisions.
Evaluate CG Oncology,'s management efficiency
CG Oncology, Common has return on total asset (ROA) of (0.157) % which means that it has lost $0.157 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1976) %, meaning that it created substantial loss on money invested by shareholders. CG Oncology,'s management efficiency ratios could be used to measure how well CG Oncology, manages its routine affairs as well as how well it operates its assets and liabilities. As of the 2nd of December 2024, Return On Tangible Assets is likely to drop to -0.26. In addition to that, Return On Capital Employed is likely to drop to -0.31. At this time, CG Oncology,'s Non Current Assets Total are very stable compared to the past year. As of the 2nd of December 2024, Non Currrent Assets Other is likely to grow to about 4.9 M, while Total Assets are likely to drop about 148.8 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 42.67 | 44.80 | |
| Tangible Book Value Per Share | 42.67 | 44.80 | |
| Enterprise Value Over EBITDA | (2.76) | (2.90) | |
| Price Book Value Ratio | 0.87 | 0.83 | |
| Enterprise Value Multiple | (2.76) | (2.90) | |
| Price Fair Value | 0.87 | 0.83 | |
| Enterprise Value | 153.2 M | 145.5 M |
The management team at CG Oncology, has a track record of steering the company towards sustained growth. Evaluating their strategies helps in understanding the stock's long-term potential.
Enterprise Value Revenue 2.6 K | Revenue 684 K | Quarterly Revenue Growth 3.778 | Revenue Per Share 0.015 | Return On Equity (0.20) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific CG Oncology, insiders, such as employees or executives, is commonly permitted as long as it does not rely on CG Oncology,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases CG Oncology, insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Corleen Roche over a month ago Acquisition by Corleen Roche of 93600 shares of CG Oncology, at 36.63 subject to Rule 16b-3 | ||
Song Hong Fang over a month ago Acquisition by Song Hong Fang of 15600 shares of CG Oncology, at 36.63 subject to Rule 16b-3 | ||
Decheng Capital Global Life Sciences Fund Iv Lp over six months ago Conversion by Decheng Capital Global Life Sciences Fund Iv Lp of 3628198 shares of CG Oncology, | ||
Bellete Ambaw over six months ago CG Oncology exotic insider transaction detected |
CG Oncology, Corporate Filings
8K | 12th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
13A | 4th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
F4 | 8th of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
CG Oncology, Earnings per Share Projection vs Actual
CG Oncology, Corporate Management
| Bing Kung | Vice Development | Profile | |
| Joshua Patterson | General Officer | Profile | |
| Swapnil Bhargava | Chief Officer | Profile | |
| Vijay MD | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CG Oncology, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CG Oncology,. If investors know CGON will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CG Oncology, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (15.87) | Revenue Per Share 0.015 | Quarterly Revenue Growth 3.778 | Return On Assets (0.16) | Return On Equity (0.20) |
The market value of CG Oncology, Common is measured differently than its book value, which is the value of CGON that is recorded on the company's balance sheet. Investors also form their own opinion of CG Oncology,'s value that differs from its market value or its book value, called intrinsic value, which is CG Oncology,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CG Oncology,'s market value can be influenced by many factors that don't directly affect CG Oncology,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CG Oncology,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if CG Oncology, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CG Oncology,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.